pharma-biotech-company-44.html
Novo Annual Report 2015
45 / 72
novo seeds investments and portfolio 2015 acesion pharma aps
develops
new therapies for the medical treatment of atrial fibrillation, the most
com
mon type of cardiac arrhythmia.
www
.acesionpharma.
com
adenium biotech aps focuses on the development and
com
mercialisation of novel antibiotics for the treatment of multi-drug resistant bacterial infections.
www
.adeniumbiotech.
com
affinicon aps
develops
antibody-drug conjugate technology that targets macrophages for the treatment of inflammatory diseases and other indications where macrophages are involved (e.g. cancer).
www
.affinicon.
com
avilex pharma aps
develops
dimeric peptides that target psd95 for the treatment of ischaemic stroke.
www
.avilexpharma.
com
denator ab
develops
, markets and sells instruments that help scientists stabilise biological samples, such as tissue sections or biopsies, from the moment of sampling.
www
.denator.
com
forendo pharma ltd
develops
drugs for tissue- specific regulation of sex hormone effects.
www
.forendo.
com
galecto biotech ab
develops
anti-fibrotic and anti-inflammatory treatments based on small molecules of galectin modulators. the
com
pany?s lead programme is in development for idiopathic pulmonary fibrosis.
www
.galecto.
com
glionova ab is developing a small molecule drug for the treatment of glioblastoma multiforme, the most
com
mon and aggressive primary brain cancer.
www
.glionova.
com
io biotech aps is developing a novel immunotherapy for cancer by targeting a mechanism used by tumour cells to evade immune responses. http://
www
.iobiotech.
com
/ lysogene sa is a clinical-stage biotech
com
pany working in the field of gene therapy. the
com
pany?s therapies target severe genetic pathologies of the central nervous system in children.
www
.lysogene.
com
minervax aps is developing a novel vaccine candidate against group b streptococci, which is the leading cause of life-threatening bacterial infections in newborn babies.
www
.minervax.
com
pcovery aps
develops
first-in-class drugs for treatment of invasive fungal infections by targeting an essential and highly conserved
com
ponent of the fungal cell membrane.
www
.pcovery.
com
reapplix aps is developing a device that produces a fully autologous dressing for wound care, particularly difficult-to-heal diabetic foot ulcers.
www
.reapplix.
com
rspr pharma
develops
new medical approaches for the treatment of respiratory diseases, including early-onset allergic asthma. http://
www
.rsprpharma.
com
/ biosyntia is a biotech start-up within synthetic biology and metabolic engineering. the
com
pany
develops
biocatalysts at an unprecedented speed and efficiency by employing a patent pending high- throughput screening technology. http://biosyntia.
com
/ inthera bioscience is a swiss biotech
com
pany targeting hpv+ head and neck cancer (hnscc) and/or hpv+ genitourinary cancer as initial indication(s). epitherapeutics aps
develops
novel innovative cancer drugs based on world-leading research in epigenetics. in 2015, the
com
pany was acquired by gilead sciences inc.
www
.epitherapeutics.
com
. new investments portfolio adenium biotech glionova t h e r a p e u t i c s exit annual review 2015 45 novo seeds
epitherapeutics-research-novo-46.html
